Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDerwent London Regulatory News (DLN)

Share Price Information for Derwent London (DLN)

Share Price is delayed by 15 minutes
Get Live Data
1,843.00    -16.00 (-0.86%)
Bid:
1,843.00
Ask:
1,845.00
Spread: 2.00 (0.109%)
Market Cap: £2.06b
DLN Live PriceLast checked at - London Stock Exchange

Intraday Derwent London Share Chart

Planning Consent

29 Feb 2008 07:01

Derwent London PLC29 February 2008 29 February 2008 Derwent London plc ("Derwent London"/ "Company") DERWENT LONDON SECURES PLANNING FOR MIDTOWN OFFICE SCHEME Derwent London, one of London's most dynamic and innovative property investorsand developers, is pleased to announce that the City of London has resolved togrant planning permission for the redevelopment of 40-45 Chancery Lane, WC2which currently comprises three multi let buildings totalling 71,146 sq ft(6,610 sq m). Designed by Bennetts Associates, the proposals are for a development of 102,900sq ft (9,556 sq m) of high quality office .The key focus of the design is acentral courtyard which will be built at the rear of the scheme linking the newspace to a building which is being retained in Tooks Court. In addition, therewill be retail space fronting Chancery Lane. The scheme will be a welcome addition to Derwent London's growing portfolio ofstylish office accommodation in the Midtown area, building on the successfulrefurbishment and lettings at the Johnson Building in Hatton Garden in 2007.Located in a rapidly expanding and vibrant part of London, Chancery Lane furtherdemonstrates the Company's confidence in an area which it believes continues tooffer occupiers significant rental value. Nigel George, Director at Derwent London, commented: "The scheme was well researched to achieve divisible floorplates which willappeal to a wide range of occupiers, together with a private courtyard offeringtenants attractive break out spaces. "The proposals are in line with Derwent London's passion for high qualityoffices that will appeal to prospective tenants looking to base themselves inthis increasingly popular area." -ends- For further information please contact: Dido Laurimore/Nicole Marino, Financial Dynamics (for Derwent London): Tel: 020 7831 3113 Nigel George, Director, Derwent London Tel 020 7659 3000 Notes to editors Derwent London plc Derwent London plc was formed on 1 February 2007 following the merger of DerwentValley Holdings and London Merchant Securities and converted to REIT status on 1July 2007. The group is one of London's most innovative office specialistproperty developers and investors and is well known for its establisheddesign-led philosophy and creative management approach to development. DerwentLondon won the RIBA Client of the Year Award 2007. Derwent London's core strategy is to acquire and own a portfolio of CentralLondon property that has reversionary rents and significant opportunities toenhance and extract value through refurbishment and redevelopment. The groupowns and manages an investment portfolio of over £2.8 billion, of which £2.5billion or 93% is located in Central London, with a specific focus on the WestEnd and the areas bordering the City of London. Landmark schemes by DerwentLondon include: Qube W1, Johnson Building EC1, Davidson Building WC2 andBroadwick House W1. Approximately 50% of the London portfolio is identified as having theopportunity, through development, to achieve significant gains in floor areaand, thereby, increases in value. The existing pipeline of development andrefurbishment projects is extensive, totalling 3.3 million sq ft (306,500 sq m). This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Aug 20254:45 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNSBoard Change
12th Aug 20257:00 amRNSInterim Results
5th Aug 20257:00 amRNSNew headlease agreed at 50 Baker Street W1
31st Jul 20254:45 pmRNSTotal Voting Rights
29th Jul 20257:00 amRNSDisposal of Francis House SW1 for £55.5m
25th Jul 20257:00 amRNSExtension of £450m Revolving Credit Facility
30th Jun 20254:45 pmRNSTotal Voting Rights
18th Jun 20257:00 amRNSAdobe lease extension and expansion
12th Jun 202511:00 amRNSRedemption of £175 million Convertible Bonds
30th May 20254:45 pmRNSTotal Voting Rights
29th May 202511:15 amRNSHolding(s) in Company
23rd May 20254:05 pmRNS£250m 7-year 5.25% bond issuance
16th May 202512:00 pmRNSResults of 2025 Annual General Meeting
8th May 20257:00 amRNSFirst Quarter Business Update
1st May 202510:00 amRNSAnnual Bondholder Meeting
30th Apr 20254:45 pmRNSTotal Voting Rights
15th Apr 202510:00 amRNSAnnual Financial Report
9th Apr 20253:00 pmRNSAdditional Listing
31st Mar 20254:45 pmRNSTotal Voting Rights
31st Mar 202510:00 amRNSNotice of Q1 2025 Business Update
26th Mar 20251:00 pmRNSDirector/PDMR Shareholding
20th Mar 20254:45 pmRNSBlock listing Interim Review
7th Mar 20252:00 pmRNSDirector/PDMR Shareholding
4th Mar 20255:15 pmRNSDirector/PDMR Shareholding
28th Feb 20254:45 pmRNSTotal Voting Rights
27th Feb 20257:00 amRNSResults for the Year Ended 31 December 2024
31st Jan 20254:45 pmRNSTotal Voting Rights
30th Jan 20255:35 pmRNSHolding(s) in Company
27th Jan 20251:30 pmRNSHolding(s) in Company
9th Jan 20257:00 amRNS25 Baker Street W1 offices fully pre-let
31st Dec 202412:45 pmRNSTotal Voting Rights
3rd Dec 20247:00 amRNSAcquisition
29th Nov 20244:45 pmRNSTotal Voting Rights
7th Nov 20247:00 amRNSTHIRD QUARTER BUSINESS UPDATE
5th Nov 202412:44 pmRNSHolding(s) in Company
31st Oct 20244:45 pmRNSTotal Voting Rights
23rd Oct 20245:30 pmRNSHolding(s) in Company
16th Oct 202410:30 amRNSDirectorate Change
30th Sep 20244:45 pmRNSTotal Voting Rights
20th Sep 20244:45 pmRNSBlock listing Interim Review
19th Sep 202411:00 amRNSDirector/PDMR Shareholding
17th Sep 202411:03 amRNSHolding(s) in Company
30th Aug 20244:45 pmRNSTotal Voting Rights
23rd Aug 202411:15 amRNSAdditional Listing
8th Aug 20247:00 amRNSHalf-Year Results
31st Jul 20244:45 pmRNSTotal Voting Rights
28th Jun 20244:45 pmRNSTotal Voting Rights
12th Jun 202411:00 amRNSHolding(s) in Company
10th Jun 20244:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.